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Declining Risk of Sudden Death in Heart Failure
To the Editor: Shen et al. (July 6 issue)1 report 
declining rates of sudden death among patients 
with heart failure and reduced ejection fraction 
who were enrolled in trials spanning the period 
from 1995 through 2014. This message is one of 
hope,2 contrasting with a traditionally more pes-
simistic narrative.3
However, why use simple linear regression? 
A spline term may better fit the data in Figure 1 
(available with the full text of the article at 
NEJM.org). The patients in the control groups of 
the BEST (Beta-Blocker Evaluation of Survival) 
trial, RALES (Randomized Aldactone Evaluation 
Study), and MERIT-HF (Metoprolol CR/XL Ran-
domised Intervention Trial in Congestive Heart 
Failure) appear on inspection to be outliers; very 
few of these patients were receiving beta-blockers. 
By using a suitable spline, we can envisage a 
steep decline in the rate of sudden death through 
the mid-1990s and a flatter trend after MERIT-HF, 
when beta-blockers became standard treatment. 
Evidence supporting the use of implantable cardio-
verter–defibrillators (ICDs) for primary preven-
tion in patients with heart failure with reduced 
ejection fraction accrued thereafter.4
Selection bias is another concern. The propor-
tion of patients with baseline ICDs who were 
excluded from the trials in the analysis by Shen 
et al. increased over time, consistent with the 
trend in clinical use.5 None of the patients in the 
early trials had an ICD at baseline; the rate of 
ICD use at baseline was 2.7% in CORONA (Con-
trolled Rosuvastatin Multinational Trial in Heart 
Failure), 6.4% in GISSI-HF (Gruppo Italiano per lo 
Studio della Sopravvivenza nell’Insufficienza Car-
diaca Heart Failure Trial), 13% in EMPHASIS-HF 
(Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure), and approxi-
mately 15% in the PARADIGM-HF trial (Prospec-
tive Comparison of ARNI with ACEI to Determine 
Impact on Global Mortality and Morbidity in 
Heart Failure). Indeed, after the exclusion of pa-
tients with ICDs, the sample for analysis appeared 
to be healthier over time (e.g., 29.0% of the pa-
tients in RALES had New York Heart Association 
[NYHA] functional class IV heart failure with re-
duced ejection fraction vs. 0.8% in the PARADIGM-
HF trial) (Table S4 in the Supplementary Appen-
dix of the article, available at NEJM.org).
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To the Editor: Shen et al. describe a 44% reduc-
tion in the rate of sudden death among patients 
with heart failure and reduced ejection fraction 
who were enrolled in 12 trials conducted during 
the period from 1995 through 2014. The authors 
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associate this significant reduction with the se-
quential introduction of efficacious drugs.
However, patients who were receiving digitalis 
had a consistently increased incidence of sudden 
death (Table S5 in the Supplementary Appendix 
of the article). In a systematic review, digoxin was 
associated with an increase of 14% in the risk of 
death from any cause.1 In the ROCKET-AF trial 
(Rivaroxaban Once Daily Oral Direct Factor Xa 
Inhibition Compared with Vitamin K Antagonism 
for Prevention of Stroke and Embolism Trial in 
Atrial Fibrillation), the use of digoxin was asso-
ciated with an increase of 33% in the rate of 
sudden death.2 Therefore, the reduction in the 
rate of sudden death is also potentially attribut-
able to the decline in the administration of di-
goxin. In the BEST trial, which was conducted 
from 1995 through 1998, digoxin was adminis-
tered in 92% of the patients, whereas in the 
PARADIGM-HF trial, which had a run-in period 
from the end of 2009 through 2012, the drug 
was listed among treatments at the time of ran-
domization in only 30% of the patients.
In the United States, there was a relative re-
duction of 91% in the rate of prescription of 
digitalis among patients with heart failure dur-
ing the period from 1997 through 2012.3 This 
reduction probably contributed to the decline in 
the rate of sudden death among patients with 
heart failure and reduced ejection fraction.
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To the Editor: Shen et al. report that the risk of 
sudden death among patients with heart failure 
and reduced ejection fraction has declined sub-
stantially over the past two decades. They attri-
bute this reduction to the widespread use of 
guideline-based medical therapies, and these ther-
apies may possibly reduce the need for an ICD.
Risk assessment tools to best identify persons 
who are likely to benefit from ICDs are essential. 
Thus, it would be interesting to know how well 
the Seattle Heart Failure Model1 and the Seattle 
Proportional Risk Model2 for sudden death would 
perform in the populations from both the earlier 
and the more recent trials assessed by Shen et al. 
These models were constructed with the use of 
data from the Prospective Randomized Amlodi-
pine Survival Evaluation (PRAISE) and several 
other cohorts from the early 1990s to the early 
2000s. Thus, we hypothesize that these models 
may require modifications to adjust for the low 
incidence of sudden death observed in recent tri-
als, although these models recently were shown 
to perform fairly well in a nationwide registry 
of patients with ICDs and heart failure.3
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The authors reply: McCarthy et al. ask whether 
a spline function gives a better fit than simple 
linear regression for the trend we found in the 
risk of sudden death over time. Accordingly, we 
examined the trend using a spline model with 
the knot set at the time suggested by McCarthy 
and colleagues. However, the fit was no better 
than with the linear model (P = 0.10 by the log 
likelihood test).
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McCarthy et al. raise a second point about 
selection bias due to exclusion of patients with 
an ICD. However, the proportion of these patients 
was small and unlikely to account for our find-
ings. The “healthier” profile of patients in later 
years was accounted for by adjustment for NYHA 
functional class, along with a number of other 
confounding variables, including age, sex, left 
ventricular ejection fraction, cause of ischemia, 
previous myocardial infarction, history of hyper-
tension, and diabetes.
Cosmi et al. suggest that the use of digoxin 
may increase the risk of sudden death among 
patients with heart failure and that reducing the 
use of this treatment might have contributed to 
the trend we observed. However, this purported 
risk of digoxin has been suggested only by obser-
vational analyses that are confounded by indica-
tion and in other ways. The only large, prospective, 
randomized, placebo-controlled trial of digoxin 
in patients with heart failure and reduced ejection 
fraction did not show an increase in the rate of 
death (or sudden death) or in hospital admissions 
for ventricular arrhythmias or cardiac arrest.1
We agree with Sawano and colleagues that it 
would be of interest to develop better tools to 
identify patients who are at risk for sudden death 
(and in whom ICDs might be of most benefit). 
We have evaluated the Seattle Heart Failure 
Model,2 the Seattle Proportional Risk Model,3 and 
newer models in more contemporary trial data 
sets. Briefly, the Seattle Heart Failure Model was 
less discriminating at predicting sudden death, 
death from pump failure, and death from any 
cause in these more recent data sets than in older 
data sets. Likewise, the Seattle Proportional Risk 
Model showed poor discrimination in contem-
porary cohorts, since both models assessed 
most patients as being appropriate candidates for 
an ICD.
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Post-Traumatic Stress Disorder
To the Editor: The review by Shalev et al. (June 
22 issue)1 highlights the need for new effective 
treatments for post-traumatic stress disorder 
(PTSD). One treatment that Shalev et al. did not 
describe is animal-assisted therapy. Since my 
first proposal and description of a case involving 
such therapy,2 it has come into widespread use 
for PTSD.3 Hundreds of organizations and chap-
ters are now providing therapy animals for pa-
tients. More formal study is needed.4 A random-
ized, controlled trial of animal-assisted therapy for 
PTSD is currently under way (ClinicalTrials.gov 
number, NCT02039843). Not just dogs but horses 
and parrots are being used to treat patients with 
PTSD, including as an aid in suicide prevention 
(although such descriptions of cases have been 
anecdotal). Unlike currently used medications, 
cognitive behavioral therapy, or experimental 
treatments with unapproved medications, the use 
of magnetic fields, or interventions requiring 
close timing to the inciting traumatic event, ther-
apy with animals can be used in the acute or 
chronic phase of PTSD and for patients who have 
had sexual or war trauma.4 Such therapy has ex-
cellent adherence, along with a favorable side-
effect profile.
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